Lista de obras - Paola Bordi - Dominio Público Uruguay

2PD Monitoring of secondary drug resistance mutations in circulating tumor DNA of patients with advanced ALK positive NSCLC.

artículo científico publicado en 2016

An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity.

artículo científico publicado en 2014

Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).

artículo científico publicado en 2016

Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.

artículo científico publicado en 2011

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer

artículo científico publicado en 2015

Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.

artículo científico publicado en 2018

Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA.

artículo científico publicado en 2016

Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment.

artículo científico publicado en 2017

ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin

artículo científico publicado en 2013

Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH.

artículo científico publicado en 2015

Enteral administration of TKIs: report of a response to ceritinib in an ALK-positive NSCLC patient and literature review

artículo científico publicado en 2018

Gene mutations in small-cell lung cancer (SCLC): results of a panel of 6 genes in a cohort of Italian patients

artículo científico publicado en 2014

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.

artículo científico publicado en 2016

Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature.

artículo científico publicado en 2017

Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report.

artículo científico publicado en 2016

Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.

artículo científico publicado en 2017

Narrative literature and cancer: improving the doctor-patient relationship

artículo científico publicado el 1 de noviembre de 2012

Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: a case report

artículo científico publicado en 2014

Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment.

artículo científico publicado en 2017

Patients' Attitudes and Physicians' Perceptions Toward Maintenance Therapy for Advanced Non-Small-cell Lung Cancer: A Multicenter Italian Survey.

artículo científico publicado en 2016

Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients

artículo científico publicado en 2015

Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy

artículo científico publicado en 2017

Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors

artículo científico

Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.

artículo científico publicado en 2016

Lista de obras de Paola Bordi

2PD Monitoring of secondary drug resistance mutations in circulating tumor DNA of patients with advanced ALK positive NSCLC.

An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity.

Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).

Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer

Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.

Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA.

Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment.

ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin

Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH.

Enteral administration of TKIs: report of a response to ceritinib in an ALK-positive NSCLC patient and literature review

Gene mutations in small-cell lung cancer (SCLC): results of a panel of 6 genes in a cohort of Italian patients

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.

Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature.

Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report.

Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.

Narrative literature and cancer: improving the doctor-patient relationship

Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: a case report

Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment.

Patients' Attitudes and Physicians' Perceptions Toward Maintenance Therapy for Advanced Non-Small-cell Lung Cancer: A Multicenter Italian Survey.

Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients

Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy

Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors

Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.